AngioDynamics (NASDAQ:ANGO) (NASDAQ: ANGO) is a global medical technology company specializing in the design, development and commercialization of innovative, minimally invasive medical devices used by healthcare providers for vascular access, peripheral vascular disease and oncology applications. Headquartered in Latham, New York, AngioDynamics offers a broad portfolio of products, including power-injectable peripherally inserted central catheters (PICCs), midlines, ports, peripheral intervention devices, biopsy and drainage catheters, as well as tumor ablation tools and embolization microspheres.
Within its vascular access segment, the company’s offerings include long-term and midline catheter systems that facilitate safe and reliable delivery of fluids, medications and nutritional support. The peripheral vascular business provides balloon angioplasty catheters, snares for foreign body retrieval, thrombectomy devices for clot removal and atherectomy systems for plaque debulking in arteries and veins. In the interventional oncology arena, AngioDynamics markets radiofrequency ablation and microwave ablation systems, along with embolic therapies designed to selectively block blood supply to tumors.
Founded in 1988, AngioDynamics has expanded its reach across more than 80 countries through direct sales channels and distribution partners. The company serves hospitals, oncology centers, specialized clinics and research institutions, with manufacturing facilities located in the United States, Ireland and Singapore. Its commitment to research and development drives periodic product launches and enhancements aimed at improving clinical outcomes, reducing procedure times and lowering overall healthcare costs.
Under the leadership of President and Chief Executive Officer Michael J. DePalma, AngioDynamics emphasizes collaboration with healthcare professionals, clinical trial support and ongoing training programs. The company’s management team combines expertise in medical device innovation, regulatory affairs and global commercial strategy to address evolving patient needs and advance minimally invasive technologies in the treatment of vascular and oncologic conditions.
